ARMP vs ELMD
ARMP: Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections. ELMD: Electromed provides innovative airway clearance therapy through its SmartVest systems to help patients with chronic pulmonary conditions breathe easier.
Side-by-side fundamentals
| Metric | ARMP | ELMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.24 | $39.52 | |
| Market cap as of 2026-07-23 | $194M | $336M | |
| P/E as of 2026-07-23 | n/a | 33.21 | |
| PEG as of 2026-07-23 | -0.00 | 0.76 | ARMP lower |
| Net margin as of 2026-07-23 | -5432.8% | +14.1% | ELMD higher |
| Gross margin as of 2026-07-23 | n/a | +78.4% | |
| Operating margin as of 2026-07-23 | -715.6% | +18.3% | ELMD higher |
| ROE as of 2026-07-23 | -120.0% | +22.1% | ELMD higher |
| ROA as of 2026-07-23 | -356.6% | +18.2% | ELMD higher |
| Debt / equity as of 2026-07-23 | 1.38 | 0.00 | ELMD lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.7% | +16.8% | ELMD higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +15.4% | |
| Beta as of 2026-07-23 | 1.36 | 0.51 | |
| 1-year return as of 2026-07-22 close | +123.0% | +123.6% | ELMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.